EP
TLSI icon

Essential Partners’s TriSalus Life Sciences TLSI Stock Holding History

Essential Partners’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432 Buy
95
+52
+121% +$207 ﹤0.01% 2508
2026
Q1 		$172 Buy
43
+21
+95% +$103 ﹤0.01% 2635
2025
Q4 		$154 Hold
22
– – ﹤0.01% 2483
2025
Q3 		$102 Buy
+22
New +$103 ﹤0.01% 2489

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Essential Partners's TLSI Position: Q2 2026 in Review

Essential Partners increased its TriSalus Life Sciences (TLSI) stake by 121% in Q2 2026, buying an estimated $207 and bringing the position to 95 shares worth $432. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

Essential Partners first reported a position in TLSI in Q3 2025 and has held it in 4 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Essential Partners held 95 shares of TriSalus Life Sciences worth $432 as of Q2 2026.
  • Essential Partners bought 52 TriSalus Life Sciences shares in Q2 2026, an estimated $207.
  • TriSalus Life Sciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2508 holding.
  • Essential Partners first reported a position in TriSalus Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.